Genmab — Maj 2020

[Bulder]

I så fald er det ikke DDB, der har stået for det, som de plejer.

[Sukkeralf]

Vi ved vel ikke noget om hvor stor en del der er tilfaldet nogen som kunne kaldes insidere

[GeorgeBest]

nej

[Bulder]

De 69090, der blev udmeldt forleden er til employees.

[GeorgeBest]

bestyrelse får ikke warrants, de får restricted stocks

[GeorgeBest]

på hjemmesiden, investors, Corporate Governance, findes compensation report, hvor detaljer findes får dem der har lyst...

[Solsen]

Insidere udnyttede ikke warrants. Det ville være meddelt.

[Solsen]

Var lidt hurtig. Bulder har svaret....

[E_L]

EHA abstracts available via https://library.ehaweb.org/eha/#!*listing=1*browseby=3*sortby=2*ce_id=1550*search=daratumumab

[E_L]

SUPERIOR ANTI-TUMOR ACTIVITY OF HEXABODY-CD38 IN PRECLINICAL MODELS OF MULTIPLE MYELOMA, B CELL LYMPHOMA AND ACUTE MYELOID LEUKEMIA https://library.ehaweb.org/eha/2020/eha25th/294801/ida.h.hiemstra.superior.anti-tumor.activity.of.hexabody-cd38.in.preclinical.html?f=listing%3D1*browseby%3D8*sortby%3D2*media%3D3*ce_id%3D1766*ot_id%3D23230*search%3Ddaratumumab*marker%3D757

[E_L]

SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL https://library.ehaweb.org/eha/2020/eha25th/293707/martin.hutchings.subcutaneous.epcoritamab.28gen3013.cd3xcd2029.in.patients.with.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab

[E_L]

EVALUATION OF PHARMACODYNAMIC BIOMARKERS OF EPCORITAMAB (GEN3013; CD3XCD20): RESULTS FROM A PHASE 1/2 DOSE-ESCALATION STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Depcoritamab

[E_L]

ok Genmab just send the mail with EHA stuff that is easier...

[Helge_LarsenPI-redaktør]

[Helge_LarsenPI-redaktør]

Tak for links E L.

[E_L]

lol. let's put the DuoHexa up also:

[E_L]

DUOHEXABODY-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO https://library.ehaweb.org/eha/2020/eha25th/293801/marije.b.overdijk.duohexabody-cd37.shows.potent.anti-tumor.activity.in.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dduohexabody

[GeorgeBest]

tak Pensionisten - 15:14

[E_L]

hang on, one more by Mrs Mateos even:

[E_L]

A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) https://library.ehaweb.org/eha/2020/eha25th/295026/marie-victoria.mateos.a.phase.1.study.of.teclistamab.a.humanized.b-cell.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dteclistamab